Federal Register / Vol. 69, No. 246 / Thursday, December 23, 2004 / Notices 76947

Board of Governors of the Federal Reserve 

System, December 17, 2004.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 04–28041 Filed 12–22–04; 8:45 am]

BILLING CODE: 6210–01–S

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices, 

Acquisitions of Shares of Bank or 

Bank Holding Companies; Correction

This notice corrects a notice (FR Doc. 

04-27578) published on page 75314 of 

the issue for Thursday, December 16, 

2004.

Under the Federal Reserve Bank of St. 

Louis heading, the entry for Martin B. 

Rowe, Harrisburg, Illinois, is revised to 

read as follows:

A. Federal Reserve Bank of St. Louis

(Randall C. Sumner, Vice President) 411 

Locust Street, St. Louis, Missouri 

63166–2034:

1. Martin B. Rowe, Harrisburg, 

Illinois, individually and as a member 

of the Rowe Family Control Group, 

which consists of Martin B. Rowe, the 

Burt H. Rowe, Jr. Marital Trust and the 

Anne Rowe Family Trust, all of 

Harrisburg, Illinois; Marianna R. Deal, 

Rachelle L. Rowe, and Caroline C. 

Rowe, all of St. Louis, Missouri; and 

Anne Rowe, St. Louis, Missouri; to 

acquire control of First Eldorado 

Bancshares, Inc., Eldorado, Illinois, and 

thereby indirectly acquire control of 

Dana Bancorp, Inc., Dana, Indiana, The 

First National Bank of Dana, Dana 

Indiana, and First State Bank of 

Eldorado, Eldorado, Illinois.

Comments on this application must 

be received by January 3, 2005.

Board of Governors of the Federal Reserve 

System, December 17, 2004.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 04–28063 Filed 12–22–04; 8:45 am]

BILLING CODE 6210–01–S

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and 

Mergers of Bank Holding Companies

The companies listed in this notice 

have applied to the Board for approval, 

pursuant to the Bank Holding Company 

Act of 1956 (12 U.S.C. 1841 et seq.) 

(BHC Act), Regulation Y (12 CFR Part 

225), and all other applicable statutes 

and regulations to become a bank 

holding company and/or to acquire the 

assets or the ownership of, control of, or 

the power to vote shares of a bank or 

bank holding company and all of the 

banks and nonbanking companies 

owned by the bank holding company, 

including the companies listed below.

The applications listed below, as well 

as other related filings required by the 

Board, are available for immediate 

inspection at the Federal Reserve Bank 

indicated. The application also will be 

available for inspection at the offices of 

the Board of Governors. Interested 

persons may express their views in 

writing on the standards enumerated in 

the BHC Act (12 U.S.C. 1842(c)). If the 

proposal also involves the acquisition of 

a nonbanking company, the review also 

includes whether the acquisition of the 

nonbanking company complies with the 

standards in section 4 of the BHC Act 

(12 U.S.C. 1843). Unless otherwise 

noted, nonbanking activities will be 

conducted throughout the United States. 

Additional information on all bank 

holding companies may be obtained 

from the National Information Center 

website at www.ffiec.gov/nic/.

Unless otherwise noted, comments 

regarding each of these applications 

must be received at the Reserve Bank 

indicated or the offices of the Board of 

Governors not later than January 18, 

2005.

A. Federal Reserve Bank of Boston

(Richard Walker, Community Affairs 

Officer) 600 Atlantic Avenue, Boston, 

Massachusetts 02106–2204:

1. The Royal Bank of Scotland Group 

plc, Edinburgh, Scotland and its 

subsidiaries, The Royal Bank of 

Scotland plc, Edinburgh, Scotland, 

RBSG International Holdings Ltd, 

Edinburgh, Scotland, and Citizens 

Financial Group, Inc., Providence, 

Rhode Island; to acquire 100 percent of 

the voting shares of Citizens 

Bank,National Association, Albany, 

New York, a de novo bank.

B. Federal Reserve Bank of Dallas

(W. Arthur Tribble, Vice President) 2200 

North Pearl Street, Dallas, Texas 75201–

2272:

1. One World Holding, Inc., Dallas, 

Texas; to become a bank holding 

company by acquiring 100 percent of 

the voting shares of One World Bank, 

Dallas, Texas, a de novo bank.

Board of Governors of the Federal Reserve 

System, December 17, 2004.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 04–28064 Filed 12–22–04; 8:45 am]

BILLING CODE 6210–01–S

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–5036–N] 

Medicare Program; Solicitation for 

Proposals for the Cancer Prevention 

and Treatment Demonstration for 

Ethnic and Racial Minorities

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS.

ACTION: Notice.

SUMMARY: This notice informs interested 

parties of an opportunity to apply for 

cooperative agreements to implement 

and operate demonstration projects 

under the Cancer Prevention and 

Treatment Demonstration for Ethnic and 

Racial Minorities as required by Section 

122 of the Medicare, Medicaid, and 

SCHIP Benefits Improvement and 

Protection Act of 2000 (BIPA). In 

addition, this notice contains 

information on how to obtain the 

complete solicitation and supporting 

information.

DATES: Applications will be considered 

timely if we receive them on or before 

March 23, 2005.

ADDRESSES: Mail applications to—

Centers for Medicare & Medicaid 

Services; Office of Operations 

Management, AGG, Cooperative 

Agreements Management Staff; 

Attention: Judith L. Norris; 7500 

Security Boulevard, Mailstop C2–21–15; 

Baltimore, Maryland 21244–1850. 

Please refer to file code CMS–5036–N 

on the application. Because of staffing 

and resource limitations, we cannot 

accept applications by facsimile (FAX) 

transmission. Applications postmarked 

after the closing date, or postmarked on 

or before the closing date but not 

received in time for panel review, will 

be considered late applications.

FOR FURTHER INFORMATION CONTACT:

Diane Merriman, CMS Project Officer, at 

(410) 786–7237 or 

CPTDEMO@cms.hhs.gov. General 

information regarding this initiative is 

available on the DHHS Web site at

http://www.grants.gov.

SUPPLEMENTARY INFORMATION: 

I. Background 

Section 122(b) of the Medicare, 

Medicaid, and SCHIP Benefits 

Improvement and Protection Act of 

2000 (BIPA) (Pub. L. 106–554) requires 

us to evaluate best practices in the 

private sector, community programs, 

and academic research to identify 

methods that reduce disparities among 

76948 Federal Register / Vol. 69, No. 246 / Thursday, December 23, 2004 / Notices 

individuals of ethnic and racial 

minority groups in the prevention and 

treatment of cancer. 

As specified in Sections 122(a) and (b) 

of BIPA, we are to design and 

implement at least nine demonstration 

projects in specific target populations 

for the purpose of developing models 

and evaluating methods that: (1) 

Improve the quality of items and 

services provided to target individuals 

in order to facilitate reduced disparities 

in early detection and treatment of 

cancer; (2) improve clinical outcomes, 

satisfaction, quality of life, and 

appropriate use of Medicare-covered 

services and referral patterns among 

those target individuals with cancer; (3) 

eliminate disparities in the rate of 

preventive cancer screening measures; 

and (4) promote collaboration with 

community-based organizations to 

ensure cultural competency of health 

care professionals and linguistic access 

for persons with limited English 

proficiency. 

Each of the following four 

legislatively-mandated target 

populations are required to be the 

subject of two separate demonstration 

projects: American Indians (including 

Alaskan Natives, Eskimos and Aleuts); 

Asian Americans and Pacific Islanders; 

Blacks; and Hispanics. At least one of 

the nine required demonstration 

projects must be implemented in a rural 

area, and one must be implemented in 

an inner-city area. In addition, one of 

the nine demonstration projects must be 

implemented in the Pacific Islands. 

If the initial demonstration evaluation 

indicates that these projects: (1) Reduce 

Medicare expenditures; or (2) do not 

increase Medicare expenditures, reduce 

ethnic and racial health disparities, and 

increase beneficiary and health care 

provider satisfaction, the existing 

demonstration projects will continue, 

and the number of demonstration 

projects may be expanded in the future.

II. Provisions of the Notice 

The purpose of this notice is to inform 

interested parties of an opportunity to 

apply for cooperative agreements to 

implement cancer prevention and 

treatment demonstration projects for 

ethnic and racial minorities. 

As specified in Section 122 of BIPA, 

we will award at least nine cooperative 

agreement demonstration projects that 

will identify methods to reduce 

disparities in early cancer screening, 

diagnosis, and treatment for Black, 

Hispanic, Asian American and Pacific 

Islander, and American Indian 

(including Alaskan Natives, Eskimos, 

and Aleuts) Medicare beneficiary 

populations. Award recipients are 

expected to use the best available 

scientific evidence to identify promising 

models of cancer screening, diagnosis 

and treatment interventions to promote 

health and the appropriate utilization of 

Medicare covered services, eliminate 

disparities in cancer detection and 

treatment among ethnic and racial 

populations of Medicare beneficiaries, 

and provide information to improve the 

effectiveness of the Medicare program. 

The Congress authorized the Cancer 

Prevention and Treatment 

Demonstration for Ethnic and Racial 

Minorities project for a potentially 

indefinite period of time, and 

appropriated $25 million in funding for 

the initial phase of the program. The 

demonstration projects will have a 3- to 

5-year operation period. We will 

consider an award of up to $50,000 per 

demonstration project to cover initial 

implementation costs. The entire award 

will not be made initially but will be 

distributed incrementally between the 

time of conditional awards and the 

approval of the demonstration by the 

Office of Management and Budget 

(OMB). We also expect the costs of 

conducting these demonstration projects 

to range from $400,000 to $1.5 million 

per project per year. These costs will be 

reimbursed through capitation payment 

to the demonstration site. No State or 

local matching funds are required. 

Furthermore, we anticipate that projects 

will be awarded in mid-2005, and that 

project startup activities would begin 

immediately after completion of the 

waiver cost process (in late 2005). 

The facilitation activities to be funded 

under these demonstration projects will 

focus on three areas of potential cancer 

disparity reduction: screening, 

diagnosis, and treatment. The applicant 

will provide facilitation services for two 

populations: (1) Medicare beneficiaries 

belonging to a defined ethnic or racial 

minority group who do not have a 

current diagnosis of cancer before 

enrollment in the demonstration project; 

and (2) Medicare beneficiaries belonging 

to a defined ethnic or racial minority 

who have been diagnosed with cancer 

before enrollment in the demonstration 

project. 

For the first population, the applicant 

must propose strategies for improving 

outcomes for cancers of the breast, 

cervix, colon and/or rectum, and 

prostate through facilitation of: (1) 

Cancer screening services; (2) follow-up 

of abnormal findings and diagnosis; and 

(3) improved access to and follow-up of 

treatment and adjuvant treatment 

services. For the second population, the 

applicant must propose facilitation 

strategies to improve access to and 

follow-up of treatment and adjuvant 

treatment services for confirmed 

diagnosis of at least one of the 

demonstration-specified cancers and/or 

lung cancer. 

Potentially qualified applicants 

include, but are not limited to: Disease 

management organizations; health 

insurers; physician group practices; 

coordinated care services providers; 

provider-sponsored organizations; 

academic medical centers; 

comprehensive cancer centers; special 

population networks; community 

clinical oncology programs; communitybased health organizations; community 

health centers; federally qualified health 

centers; minority institutions such as, 

among others, Historically Black 

Colleges and Universities, Hispanic 

Serving Institutions, and Hispanic 

health organizations and associations; 

tribal organizations; a consortium of the 

above entities; or any other legal entity 

that the Secretary determines to be 

appropriate. We strongly encourage the 

establishment of collaborative consortia 

for this demonstration. The applicant 

must demonstrate its ability to 

effectively deliver cancer screening, 

diagnosis, and treatment facilitation 

services on a capitation basis to one or 

more of the following populations: 

Black, Hispanic, Asian American and 

Pacific Islander, and American Indian 

(including Alaskan Natives, Eskimos, 

and Aleuts) Medicare beneficiaries. 

Interested parties are to obtain complete 

solicitation and supporting information 

on the DHHS Web site at http://

www.grants.gov.

III. Collection of Information 

Requirements 

The application associated with this 

demonstration entitled ‘‘Medicare 

Waiver Demonstration Application’’ is 

currently approved under OMB 

approval number 0938–0880, with a 

current expiration date of July 31, 2006. 

In addition, the collection 

requirements associated with this 

demonstration do not impose 

information collection and record 

keeping requirements, because they 

meet the ‘‘information’’ definition 

exception under 5 CFR 1320.3(h)(5) 

which states: ‘‘ ‘Information’ does not 

generally include items in the following 

categories: (5) facts or opinions obtained 

initially or in follow-on requests, from 

individuals (including individuals in 

control groups) under treatment or 

clinical examination in connection with 

research on or prophylaxis to prevent a 

clinical disorder, direct treatment of that 

disorder, or the interpretation of 

biological analyses of body fluids, 

tissues, or other specimens, or the 

Federal Register / Vol. 69, No. 246 / Thursday, December 23, 2004 / Notices 76949

identification or classification of such 

specimens. * * *’’

Authority: Section 122 of the Medicare, 

Medicaid, and SCHIP Benefits Improvement 

and Protection Act of 2000 (BIPA) (Pub. L. 

106–554).

(Catalog of Federal Domestic Assistance 

Program No. 93.779, Medical Assistance 

Program; No. 93.773, Medicare—Hospital 

Insurance Program; and No. 93.774, 

Medicare—Supplementary Medical 

Insurance Program)

Dated: September 15, 2004. 

Mark B. McClellan, 

Administrator, Centers for Medicare & 

Medicaid Services.

[FR Doc. 04–27527 Filed 12–14–04; 8:45 am] 

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Statement of Organization, Functions 

and Delegations of Authority 

This notice amends Part K of the 

Statement of Organization, Functions 

and Delegations of Authority of the 

Department of Health and Human 

Services (HHS), Administration for 

Children and Families (ACF), as 

follows: Chapter KA, Office of the 

Assistant Secretary for Children and 

Families (OAS) as last amended October 

16, 2001 (66 FR 52627) and Chapter KN, 

Office of Public Affairs (OPA) as last 

amended January 2, 1998 (63 FR 81–87). 

This notice announces the transfer of 

the Freedom of Information Act (FOIA) 

functions from the Office of the 

Executive Secretariat and places them in 

the Division of Public Information, 

Office of Public Affairs. 

These Chapters are amended as 

follows: 

I. Chapter KA, Office of the Assistant 

Secretary for Children and Families 

A. Delete KA.20 Functions, Paragraph 

C in its entirety and replace with the 

following: 

C. The Executive Secretariat (ExecSec) 

ensures that issues requiring the 

attention of the Assistant Secretary, 

Deputy Assistant Secretaries and/or 

executive staff are addressed on a timely 

and coordinated basis and facilitates 

decisions on matters requiring 

immediate action including White 

House, Congressional and Secretarial 

assignments. ExecSec serves as the ACF 

liaison with the HHS Executive 

Secretariat. It receives, assesses and 

controls incoming correspondence and 

assignments to the appropriate ACF 

component(s) for response and action 

and provides assistance and advice to 

ACF staff on the development of 

responses to correspondence. ExecSec 

provides assistance to ACF staff on the 

use of the controlled correspondence 

system. ExecSec coordinates and/or 

prepares congressional correspondence, 

tracks development of periodic reports 

and facilitates Departmental clearances. 

II. Chapter KN, Office of Public Affairs 

A. Delete KN.00. Mission in its 

entirety and replace with the following: 

KN.00 Mission. The Office of Public 

Affairs (OPA) develops, directs and 

coordinates public affairs and 

communications services for ACF. OPA 

serves as liaison with the Office of the 

Secretary, Office of Public Affairs in 

processing the Freedom of Information 

Act inquiries for ACF and coordinates 

hot line calls received by the Office of 

Inspector General and the Government 

Accountability Office relating to ACF 

operations and personnel. OPA provides 

leadership, direction and oversight in 

promoting ACF’s public affairs policies, 

programs and initiatives. OPA also 

provides printing and distribution 

services for ACF. 

B. Delete KN.20 Functions paragraph 

B, in its entirety and replace with the 

following: 

B. The Division of Public Information 

(the Division) develops and implements 

public affairs strategies to achieve ACF 

program objectives in coordination with 

other ACF components. The Division 

coordinates news media relations 

strategy; responds to all media inquiries 

concerning ACF programs and related 

issues; develops fact sheets, news 

releases, feature articles for magazines 

and other publications on ACF 

programs and initiatives; and manages 

preparation and clearance of speeches 

and official statements on ACF 

programs. The Division coordinates 

regional public affairs policies and 

public affairs activities pertaining to 

ACF programs and initiatives. The 

Division Director serves as liaison to the 

Office of the Secretary, Office of Public 

Affairs in processing the Freedom of 

Information Act inquiries and 

coordinates hot line calls received by 

the Office of Inspector General and the 

Government Accountability Office 

relating to ACF operations and 

personnel.

Dated: December 14, 2004. 

Wade F. Horn, 

Assistant Secretary for Children and Families.

[FR Doc. 04–28052 Filed 12–22–04; 8:45 am] 

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing

AGENCY: National Institutes of Health, 

Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing.

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Non-Small Cell Lung Cancer Cell Line 

H3255

Herbert K. Oie et al. (NCI) 

DHHS Reference No. E–028–2005/0—

Research Tool 

Licensing Contact: Mojdeh Bahar; 301/

435–2950; baharm@mail.nih.gov.

This invention, the H3255 cell line, 

was initiated from malignant cells 

isolated from the pleural effusion from 

a non-smoker Caucasian female. The 

cultured tumor cells, identified as NonSmall Cell Lung Carcinoma Cells 

(NSCLC), were found to have a mutation 

within the EGFR gene that made them 

very sensitive to certain growth 

inhibiting drugs, such as gefitinib 

(iressa). Cell lines sensitive to growth 

inhibitors could be used in the 

treatment of cancer as potential 

chemotherapeutic agents. 

LRATlerin, Related Compounds and 

Methods of Use 

Denise P. Simmons (NCI) 

U.S. Provisional Application No. 60/

613,256 filed 27 Sep 2004 (DHHS 

Reference No. E–349–2004/0–US–01) 

Licensing Contact: Mojdeh Bahar; 301/

435–2950; baharm@mail.nih.gov.

The invention discloses combinations 

of anti-tumor agents and antiVerDate jul<14>2003 16:12 Dec 22, 2004 Jkt 205001 PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 E:\FR\FM\23DEN1.SGM 23DEN1